Brivaracetam patent expiry?

Brivaracetam (generic name) – Patent Landscape & Expected Expiry

Key take‑aways

1. Composition‑of‑matter patents are long expired – the core chemical is no longer protected, so the primary barrier is not the compound itself.

2. Method‑of‑treatment and formulation patents are the main current barriers – these are still active and will expire between 2028 and 2031. Generic manufacturers would need to wait until all relevant patents expire or secure a post‑approval exclusivity waiver.

3. FDA market exclusivity ends in 2027 – even if patents expire earlier, Pfizer can still prevent generic competition in the U.S. until that year.

4. EU situation – In the European Union the situation is similar, with most key patents expiring around 2029–2030. Generic entry is unlikely until after those dates unless Pfizer’s patents are challenged or expire sooner.

5. What this means for patients – For the time being, Briviact remains a branded medication. Generic options are expected only post‑2030 once all remaining patents and exclusivity periods lapse.

Practical advice

• Check the latest IP filings – Patent status can change (e.g., new secondary patents, extensions, or litigation).
• Watch for generic filings – Once patents expire, generic manufacturers may file for approval, but approval and launch can take 1–2 years.
• Insurance & cost considerations – Until generics appear, cost will remain that of the branded drug.

If you need the exact filing numbers or more detailed legal status for a specific jurisdiction (e.g., India, Canada, Australia), let me know and I can pull the most recent data for you.